AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33638801
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no evolocumab injection)
Trial: 33314799
Drug: Mock laser
RxNorm normalized name: mockernut extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock laser acupuncture (ML)
Trial: 32541773
Drug: Inhaled Nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Nitric Oxide (iNO) 160 ppm plus oxygen/air for 30 min, five times/day, up to 5 days
Trial: 32096884
Drug: Self-administered acupressure
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered acupressure intervention
Trial: 34883305
Drug: Blueberry intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blueberry intake (26 g freeze-dried blueberries)
Trial: 34883305
Drug: Placebo (26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (26 g isocaloric matched placebo)
Trial: 37170922
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg subcutaneously every 2 weeks
Trial: 35717166
Drug: MTV calculated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTV calculated using SUV140%L threshold
Trial: 35717166
Drug: TLG calculated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLG calculated using SUV140%L threshold
Trial: 34085953
Drug: Hypoglycemia (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglycemia (plasma glucose < 3.0 mmol/L)
Trial: 33724883
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg daily of canagliflozin
Trial: 34879449
Drug: Dupilumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (100 mg for those weighing ≤30 kg and 200 mg for those weighing >30 kg)
Trial: 33606918
Drug: Acarbose 50
RxNorm normalized name: acarbose 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg
Trial: 33267925
Drug: AMPH EROS
RxNorm normalized name: AMPH-b
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMPH EROS (7.5 mL of 2.5 mg/mL, equivalent to 18.8 mg of amphetamine base)
Trial: 33267925
Drug: ER MAS
RxNorm normalized name: E-Z Spacer Mask
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER MAS (30 mg capsule, equivalent to 18.8 mg of amphetamine base)
Trial: 33341413
Drug: DISCO intervention
RxNorm normalized name: DISC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DISCO intervention group (systematic follow‐up by a dietitian to adhere to the Dietary Approaches to Stop Hypertension nutrition model together with optimal medical therapy [OMT])
Trial: 32805740
Drug: n-3 LC-PUFAs
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 LC-PUFAs (1 g of fish oil 3 times a day for 2 months containing 360 mg EPA and 240 mg DHA)
Trial: 32707001
Drug: MRG-110 (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRG-110 (0.01 to 1.5 mg/kg body weight)
Trial: 32707001
Drug: MRG-110 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRG-110 (1.5 mg/kg)
Trial: 35767935
Drug: Topical aloe
RxNorm normalized name: Alo Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aloe vera gel
Trial: 35263681
Drug: holoBLG lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: holoBLG lozenge
Trial: 32745734
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/d) plus Clopidogrel (75 mg/d) for 6 months followed by random assignment to aspirin plus clopidogrel for an additional 6 months
Trial: 32745734
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/d) plus Placebo for an additional 6 months
Trial: 32745734
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/d) plus Placebo for an additional 6 months
Trial: 35710395
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training with post-exercise sauna treatments (ET + S, n = 8)
Trial: 35710395
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training without sauna treatments (ET, n = 7)
Trial: 35598636
Drug: Multi-component edetate
RxNorm normalized name: EDETATE
DrugBank: Edetate sodium (DB13404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component edetate disodium (Na2EDTA)‐based chelation solution, 40 weekly infusions
Trial: 35598636
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily oral, high-dose multivitamin and mineral supplements
Trial: 35598636
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group for chelation therapy)
Trial: 35598636
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control group for multivitamin and mineral supplements)
Trial: 32618115
Drug: COMBIND intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COMBIND intervention (specialized behavioural training plus a tablet-based mHealth application)
Trial: 39696604
Drug: Treatment-as-usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU) group
Trial: 36028775
Drug: Individual nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual nutrition therapy (five in person visits and three phone calls) and freely delivered energy- and protein-rich foods
Trial: 36028775
Drug: Individual nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual nutrition therapy
Trial: 32812964
Drug: AOB‐w (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOB‐w (350 mg)
Trial: 39566128
Drug: Radiofrequency treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency treatment
Trial: 34018342
Drug: Luvadaxistat 75
RxNorm normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luvadaxistat 75 mg BID
Trial: 34018342
Drug: Luvadaxistat 300
RxNorm normalized name: Luvadaxistat
DrugBank: Luvadaxistat (DB16067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luvadaxistat 300 mg BID
Trial: 35427363
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (3000 IU daily)
Trial: 34985973
Drug: 15 to
RxNorm normalized name: ointment base no.215 TOPICAL OINTMENT (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 to 30 mg of arbaclofen (GABAB receptor agonist)
Trial: 33041200
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of the first dose to the patient
Trial: 33559294
Drug: Levofloxacin 750mg
RxNorm normalized name: LEVOFLOXACIN 750MG TAB
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750mg once daily
Trial: 33559294
Drug: Ciprofloxacin 400mg
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400mg twice daily
Trial: 34524953
Drug: Rescue intervention
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue intervention strategy (RIS) with budesonide/formoterol plus original treatment until severe pollution ended
Trial: 34524953
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group maintained on original treatment
Trial: 39547230
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT)
Trial: 33573681
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine 2% (20mg/mL)
Trial: 33573681
Drug: Intravenous NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous NaCl 0.9% (9 mg/mL)
Trial: 34208986
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein snack (HP), n = 52, containing 50 g soybean
Trial: 35597993
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care processes for antibiotic use and stewardship (control group)
Trial: 34323589
Drug: 0.1 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mmol/kg gadoteridol at a rate of 3 mL/s (group A)
Trial: 34323589
Drug: 0.1 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mmol/kg gadoteridol at a rate of 2 mL/s (group B)
Trial: 32359021
Drug: Colloidal oatmeal
RxNorm normalized name: Colloidal Oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal oatmeal lotion (Aveeno™ Eczema Therapy Moisturizing Cream)
Trial: 33208263
Drug: PEEK‐A (Ar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEEK‐A (Ar cold plasma treatment)
Trial: 33208263
Drug: PEEK‐N (N2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEEK‐N (N2 cold plasma treatment)
Trial: 33208263
Drug: PEEK‐AN (90%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEEK‐AN (90% Ar and 10% N2 mixed cold plasma treatment)
Trial: 32848380
Drug: tiotropium/olodaterol 5/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium/olodaterol 5/5 µg
Trial: 32969489
Drug: Dupilumab 2
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 2 mg kg−1
Trial: 32969489
Drug: Dupilumab 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 4 mg kg−1
Trial: 34268630
Drug: Single-crown restorations
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-crown restorations supported by short implants
Trial: 34268630
Drug: Standard length
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard length implants in conjunction with maxillary sinus floor augmentation (MSFA)
Trial: 32064596
Drug: Topical rapamycin
RxNorm normalized name: natamycin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rapamycin 0.1%
Trial: 33941638
Drug: High-dose corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose corticosteroids and nebulised epinephrine for bronchiolitis
Trial: 36217068
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (adding an anti‐staphylococcal beta‐lactam)
Trial: 36217068
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (vancomycin monotherapy)
Trial: 32168290
Drug: Tablet-based Decision
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based Decision Support Tool (DST)
Trial: 32429977
Drug: Oxytocin vaginal
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin vaginal gel (400 IU per night)
Trial: 34671971
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (cryoprecipitate administered later or not at all)
Trial: 34022880
Drug: Individualized surgery
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized surgery combined with radiotherapy and triamcinolone acetonide injection
Trial: 34634368
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (FSGTC plus imrecoxib)
Trial: 32697335
Drug: Glasdegib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib plus low-dose cytarabine (LDAC)
Trial: 33001140
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of baricitinib once daily (n=111)
Trial: 33001140
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of baricitinib once daily (n=109)
Trial: 36581937
Drug: Non-invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive treatment
Trial: 35982138
Drug: Low emotion
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low emotion control (L‐EC) training condition
Trial: 33206131
Drug: Quadratus lumborum
RxNorm normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadratus lumborum block with spinal morphine
Trial: 32506860
Drug: Thin wrist‐ankle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin wrist‐ankle acupuncture (WAA) + Fluoxetine
Trial: 32506860
Drug: Thick wrist‐ankle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thick wrist‐ankle acupuncture (WAA) + Fluoxetine
Trial: 32506860
Drug: Sham wrist‐ankle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham wrist‐ankle acupuncture (WAA) + Fluoxetine
Trial: 32646462
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa (CFA) with 300 UI rFSH and 150 UI rLH in long agonist protocol
Trial: 32646462
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa (CFA) with 300 UI rFSH and 150 UI rLH in short antagonist protocol
Trial: 35395080
Drug: Durvalumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab + low-dose bevacizumab (cohort B3)
Trial: 33979451
Drug: Fenfluramine (FFA)
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (FFA) at 0.4 mg/kg/day (n=2) or 0.7 mg/kg/day (n=4; maximum: 26 mg/day) for a mean duration of 5.3 months (range: 2–9 months)
Trial: 36884013
Drug: D1 agonist
RxNorm normalized name: PHOSPHOLIPASE D1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 agonist
Trial: 33658470
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement comprising 1197 mg of acetic acid bacteria containing 9.06 mg of ceramide
Trial: 34925649
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional therapy only)
Trial: 35065705
Drug: SCB-2019 vaccine
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB-2019 vaccine (30 µg, adjuvanted with 1.50 mg CpG-1018 and 0.75 mg alum), administered as two 0.5 mL intramuscular doses 21 days apart.
Trial: 35065705
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sodium chloride for injection).
Trial: 32683383
Drug: Ozonized water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozonized water treatment
Trial: 32683383
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (double‐distilled water)
Trial: 32861358
Drug: Fascial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascial therapy (3 weeks, 45 minutes per week)
Trial: 34045486
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma containing high titers of neutralizing SARS‐CoV‐2 antibodies (300mL)
Trial: 32041656
Drug: Intervention focusing
RxNorm normalized name: ficusin
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention focusing on both the individual and the household to enable self-management of treatment within an HIV competent household (Intervention)
Trial: 34861374
Drug: Veliparib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib monotherapy (300-400 mg twice daily)
Trial: 34861374
Drug: Veliparib during
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib during combination therapy and monotherapy
Trial: 34861374
Drug: Veliparib and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib and placebo monotherapy
Trial: 36254693
Drug: empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empagliflozin 10 mg once daily
Trial: 33819498
Drug: Etomidate 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.03 mg/kg
Trial: 33819498
Drug: Propofol 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.2 mg/kg
Trial: 33933353
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) treatment, 2 sessions at 3-week intervals
Trial: 33933353
Drug: Sham IPL
RxNorm normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham IPL treatment (Control)
Trial: 33225554
Drug: Withdrawing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawing therapy
Trial: 33225554
Drug: Withdrawing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawing therapy (non-randomized comparison)
Trial: 33225554
Drug: Withdrawing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawing therapy (among those who did not relapse)
Trial: 33225554
Drug: Withdrawing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawing therapy (in patients with TTN variants)
Trial: 34959836
Drug: Shatavari (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shatavari (1000 mg/d for 6 weeks)
Trial: 35662619
Drug: Reward Re‐Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reward Re‐Training (RRT) treatment for 10 weeks
Trial: 32166429
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 15 mg weekly
Trial: 33415859
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (nape seven needles combined with penetration needling for 30 min, once daily for 4 weeks)
Trial: 33415859
Drug: Flunarizine hydrochloride
RxNorm normalized name: flunarizine hydrochloride
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine hydrochloride capsules (5 mg, once daily for 4 weeks)
Trial: 33415859
Drug: Total effective
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total effective rate of treatment group
Trial: 34762375
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment (rehabilitation and hyperbaric oxygen)
Trial: 34802087
Drug: Nomogram developed
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram developed based on multivariable logistic regression analysis using predictors such as glucocorticoid injection history, knee OA in the contralateral side, extensor muscle strength, area of cartilage deficiency, bone marrow lesion, and meniscus extrusion.
Trial: 33574013
Drug: Double-headed capsule
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-headed capsule endoscopy (DH CE)
Trial: 33574013
Drug: Single-headed capsule
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-headed capsule endoscopy (SH CE)
Trial: 34309491
Drug: Bisphosphonate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate treatment (pamidronate, alendronate, ibandronate)
Trial: 35924008
Drug: UDCA (13–15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (13–15 mg/kg/day) + fenofibrate (200 mg/day)
Trial: 35924008
Drug: UDCA (13–15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (13–15 mg/kg/day)
Trial: 34087055
Drug: Skin whitening
RxNorm normalized name: ASCORBYL GLUCOSIDE 1.5 g in 1 mg BUCCAL EMULSION [skin whitening]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin whitening serum containing niacinamide, hydroxyphenoxy propionic acid, dipotassium glycyrrhizate, glycolic acid, and 4‐n‐butylresorcinol applied twice daily combined with a spot‐preventing SPF50+ sunscreen
Trial: 34781972
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine and perioperative gabapentin (ITM+GABA group)
Trial: 34781972
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine only (ITM group)
Trial: 32037134
Drug: internet‐based cognitive‐behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet‐based cognitive‐behavioural writing therapy (iCBT) for PTSD
Trial: 34508547
Drug: DMARD tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMARD tapering arms
Trial: 32736578
Drug: Brief Motivational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Motivational Treatment (BMT) - four 45-min sessions provided by a general psychologist with at least 3 years of primary care experience.